Business
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further support the differentiated profile of ICOTYDE, the first and only IL-23 receptor targeted oral peptide NEWARK, CA / ACCESS Newswire / March 28, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) (\"Protagonist\" or \"the Company\") today announced new one-year Phase 3 results for ICOTYDE™ (icotrokinra) were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies further support the potential of ICOTYDE as a differentiated oral therapy for patients with moderate-to-severe plaque psoriasis.\"The one-year Phase 3 results presented at AAD reinforce our belief that ICOTYDE by virtue of having IL-23 antagonist efficacy, a favorable safety profile and the convenience of a once-daily oral pill option, has the potential to meaningfully expand treatment options for people living with moderate-to-severe plaque psoriasis,\" said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. \"These findings highlight the power of Protagonist's peptide discovery platform and our ability to create highly differentiated oral medicines against clinically validated biological pathways.\"ICOTYDE is the first and only targeted oral peptide designed to precisely block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque PsO.ICOTYDE was developed using Protagonist's proprietary peptide technology platform. The Company continues to invest in its discovery engine and development pipeline, with multiple programs moving towards proof-of-concept trials designed to produce therapeutics with clinically relevant competitive differentiation.Under the license and collaboration agreement established in 2017 between Protagonist and Janssen Biotech, Inc., a Johnson & Johnson company, Johnson & Johnson is responsible for all commercial activities for ICOTYDE. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commer...